{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:50:22Z","timestamp":1779220222560,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P23060"],"award-info":[{"award-number":["P23060"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.taap.2017.06.018","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T01:02:13Z","timestamp":1498006933000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Modulation of the heart's electrical properties by the anticonvulsant drug retigabine"],"prefix":"10.1016","volume":"329","author":[{"given":"Lena","family":"Rubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Zebedin-Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xaver","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Dominguez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Todt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Kubista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlheinz","family":"Hilber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2017.06.018_bb0005","first-page":"225","article-title":"Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine","volume":"2","author":"Barrese","year":"2010","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.taap.2017.06.018_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X)","volume":"92","author":"Bialer","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.taap.2017.06.018_bb0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/BF00173013","article-title":"Noradrenaline release from rat sympathetic neurons evoked by P2-purinoceptor activation","volume":"350","author":"Boehm","year":"1994","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/pr.54.1.43","article-title":"Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors","volume":"54","author":"Boehm","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2017.06.018_bb0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.taap.2017.06.018_bb0030","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0035","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1111\/bph.13093","article-title":"Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations","volume":"172","author":"Champeroux","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1046\/j.1540-8167.2004.04099.x","article-title":"Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel","volume":"15","author":"Davie","year":"2004","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.taap.2017.06.018_bb0045","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1161\/01.CIR.0000035241.76918.6C","article-title":"Modulation of QT interval during autonomic nervous system blockade in humans","volume":"106","author":"Diedrich","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2017.06.018_bb0050","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/11594640-000000000-00000","article-title":"Novel medications for epilepsy","volume":"71","author":"Fattore","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2017.06.018_bb0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.yebeh.2012.09.021","article-title":"QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy","volume":"26","author":"Feldman","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.taap.2017.06.018_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/00912700222011210","article-title":"Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers","volume":"42","author":"Ferron","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2125.2003.01825.x","article-title":"Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects","volume":"56","author":"Ferron","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.taap.2017.06.018_bb0075","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1038\/ncomms11671","article-title":"KCNQ channel openers reverse depressive symptoms via an active resilience mechanism","volume":"7","author":"Friedman","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2017.06.018_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2012.05.007","article-title":"Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies","volume":"102","author":"Gil-Nagel","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.taap.2017.06.018_bb0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.taap.2017.06.018_bb0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","article-title":"Metabolism of retigabine (D-23129), a novel anticonvulsant","volume":"27","author":"Hempel","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2017.06.018_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mcp.2003.12","article-title":"Effects of age and sex on the disposition of retigabine","volume":"73","author":"Hermann","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2017.06.018_bb0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-003-0558-6","article-title":"Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects","volume":"58","author":"Hermann","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0105","first-page":"243","article-title":"A case of torsades de pointes probably caused by trimetaphan intoxication","volume":"24","author":"Hirata","year":"1994","journal-title":"J. Cardiol."},{"key":"10.1016\/j.taap.2017.06.018_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.RES.49.1.1","article-title":"Cellular mechanisms for cardiac arrhythmias","volume":"49","author":"Hoffman","year":"1981","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2017.06.018_bb0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00952990.2014.892951","article-title":"The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats","volume":"40","author":"Knapp","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.taap.2017.06.018_bb0120","doi-asserted-by":"crossref","first-page":"e20300","DOI":"10.1371\/journal.pone.0020300","article-title":"Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart","volume":"6","author":"Koenig","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2017.06.018_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.taap.2013.05.012","article-title":"Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile","volume":"273","author":"Koenig","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2015.06.002","article-title":"Efficacy and safety of ezogabine\/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures","volume":"30","author":"Lerche","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.taap.2017.06.018_bb0135","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1172\/JCI25537","article-title":"Long QT syndrome: from channels to cardiac arrhythmias","volume":"115","author":"Moss","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2017.06.018_bb0140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1540-8167.2005.40455.x","article-title":"Gender differences in autonomic modulation of ventricular repolarization in humans","volume":"16","author":"Nakagawa","year":"2005","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.taap.2017.06.018_bb0145","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1124\/mol.61.4.921","article-title":"Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission","volume":"61","author":"Otto","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2017.06.018_bb0150","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.taap.2017.06.018_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2017.06.018_bb0160","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/0002-9149(87)90196-2","article-title":"Arrhythmogenic actions of antiarrhythmic drugs","volume":"59","author":"Rosen","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.taap.2017.06.018_bb0165","article-title":"Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes","author":"Rubi","year":"2016","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.taap.2017.06.018_bb0170","first-page":"1063","article-title":"Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels","volume":"50","author":"Rundfeldt","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.taap.2017.06.018_bb0175","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00424-014-1487-1","article-title":"Excitation of rat sympathetic neurons via M1 muscarinic receptors independently of Kv7 channels","volume":"466","author":"Salzer","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.taap.2017.06.018_bb0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.taap.2017.06.018_bb0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0306-4522(93)90186-J","article-title":"Cyclic AMP modulates but does not mediate the inhibition of [3H]norepinephrine release by activation of alpha-2 adrenergic receptors in cultured rat ganglion cells","volume":"52","author":"Schwartz","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.taap.2017.06.018_bb0190","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1540-8167.2007.00901.x","article-title":"Autonomic tone attenuates drug-induced QT prolongation","volume":"18","author":"Smith","year":"2007","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.taap.2017.06.018_bb0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002320001106","article-title":"New molecular determinant for inactivation of the human L-type alpha1C Ca2+ channel","volume":"177","author":"Soldatov","year":"2000","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.taap.2017.06.018_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/JCNSD.S9299","article-title":"Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults","volume":"5","author":"Splinter","year":"2013","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.taap.2017.06.018_bb0205","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd3561","article-title":"Ezogabine (retigabine)","volume":"10","author":"Stafstrom","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2017.06.018_bb0210","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2017.06.018_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2009.04.197","article-title":"Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?","volume":"60","author":"Towart","year":"2009","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2017.06.018_bb0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/epi.12950","article-title":"The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors","volume":"56","author":"Treven","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.taap.2017.06.018_bb0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0165-6147(00)01662-X","article-title":"HERG K+ channels: friend and foe","volume":"22","author":"Vandenberg","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2017.06.018_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","article-title":"Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons","volume":"7","author":"Wainger","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.taap.2017.06.018_bb0235","first-page":"409","article-title":"Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures","volume":"7","author":"Weisenberg","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.taap.2017.06.018_bb0240","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjp.2008.267","article-title":"Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model","volume":"154","author":"Yao","year":"2008","journal-title":"Br. J. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17302739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17302739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T21:04:49Z","timestamp":1750367089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X17302739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":48,"alternative-id":["S0041008X17302739"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2017.06.018","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of the heart's electrical properties by the anticonvulsant drug retigabine","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2017.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}